Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
A Parkinson’s disease treatment from Neuraly, a biotech spun out from the Johns Hopkins School of Medicine, did not improve motor experiences of daily living or movement in a mid-stage trial, but the investigators did flag a better result for younger patients.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD). NLY01, Neuraly’s lead development asset, is a glucagon-like peptide 1 receptor (GLP-1R) agonist that has been demonstrated to inhibit pathological activation of microglia by binding upregulated GLP-1R in animal models of neurodegenerative diseases such as PD. In doing so, NLY01 has demonstrated the ability to inhibit neuroinflammation and prevent neuronal cell death, offering a potentially first-of-its-kind, disease-modifying therapy capable of slowing the progression of PD.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced publication in the peer-reviewed journal Acta Neuropathologica Communications of preclinical data that contributed to the therapeutic rationale for clinical evaluation of NLY01 in Alzheimer’s and Parkinson’s diseases. The research was conducted in collaboration with Dr. Ted Dawson’s lab at the Johns Hopkins School of Medicine.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc, a clinical-stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced a strategic sponsored research agreement with the University of Pennsylvania to study the use of NLY01 to therapeutically target a neuroinflammatory mechanism of glaucoma.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease. NLY01 is also being evaluated in patients with Parkinson’s disease in a Phase 2 trial initiated in February 2020.